A phase 3, continuation study to evaluate the long-term safety of asoprisnil in subjects with uterine leiomyomata
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Asoprisnil (Primary)
- Indications Uterine leiomyoma
- Focus Adverse reactions
- Sponsors Abbott Laboratories
- 28 Oct 2006 New trial record.